SCHEMBL1992443

SCHEMBL1992443

COC(=O)CNC(=O)C1CN(C(=O)OC(C)(C)C)CCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDK1 Q15118 2/20 0.43
RECQL P46063 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.38
NR1H2 P55055 1/20 0.37
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 1/20 0.36
EPHA2 P29317 1/20 0.35
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
EPHX1 P07099 1/20 0.35
THRB P10828 1/20 0.35
PTPN2 P17706 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552060 0.88 USP2 (0.44) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL388800 0.88 USP2 (0.44) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL1552443 0.88 USP2 (0.44) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL31381407 0.84 MAPT (0.44) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL31049519 0.83 USP2 (0.50) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL660978 0.83 USP2 (0.50) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL23210396 0.82 USP2 (0.49) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL8285377 0.82 USP2 (0.49) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL1439935 0.81 PDK1 (0.59) USP2SMN1; SMN2PDK1RECQLALDH1A1
SCHEMBL25630738 0.81 PDK1 (0.59) USP2SMN1; SMN2PDK1RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399681-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2013-03-19 US disclosed
US-20120302544-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS BIGNAN GILLES (US) 2012-11-29 US disclosed
EP-2513096-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-A MODULATORS Janssen Pharmaceutica, N.V. (BE) 2012-10-24 EP disclosed
US-8263781-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 US disclosed
WO-2011075565-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302544-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, IGF1R USP2 2731/4885SMN1; SMN2 3292/4885PDK1 594/4885
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, IGF1R USP2 2731/4885SMN1; SMN2 3292/4885PDK1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.